Antibody Indices of Infectious Pathogens from Serum and Cerebrospinal Fluid in Patients with Schizophrenia Spectrum Disorders

Overview

Journal Fluids Barriers CNS

Publisher Biomed Central

Date 2022 Jul 29

PMID 35906648

Authors

Kimon Runge

Agnes Balla

Bernd L Fiebich

Simon J Maier

Benjamin Pankratz

Andrea Schlump

Kathrin Nickel

Rick Dersch

Katharina Domschke

Ludger Tebartz van Elst

Dominique Endres

Affiliations

Soon will be listed here.

Abstract

Introduction: Infectious and immunological theories of schizophrenia have been discussed for over a century. Contradictory results for infectious agents in association with schizophrenia spectrum disorders (SSDs) were reported. The rationale of this study was to investigate intrathecal antibody synthesis of the most frequently discussed neurotropic pathogens using a pathogen-specific antibody index (AI) in patients with SSD in comparison to controls.

Methods: In 100 patients with SSD and 39 mentally healthy controls with idiopathic intracranial hypertension (IIH), antibodies against the herpesviruses EBV, CMV, and HSV 1/2 as well as the protozoan Toxoplasma gondii, were measured in paired cerebrospinal fluid (CSF) and serum samples with ELISA-kits. From these antibody concentrations the pathogen-specific AIs were determined with the assumption of intrathecal antibody synthesis at values > 1.5.

Results: No significant difference was detected in the number of SSD patients with elevated pathogen-specific AI compared to the control group. In a subgroup analysis, a significantly higher EBV AI was observed in the group of patients with chronic SSD compared to patients with first-time SSD diagnosis (p = 0.003). In addition, two identified outlier EBV patients showed evidence for polyspecific immune reactions (with more than one increased AI).

Conclusions: Evidence for the role of intrathecal EBV antibody synthesis was found in patients with chronic SSD compared to those first diagnosed. Apart from a possible infectious factor in SSD pathophysiology, the evidence for polyspecific immune response in outlier patients may also suggest the involvement of further immunological processes in a small subgroup of SSD patients.

Citing Articles

Microbes and Mental Illness: Past, Present, and Future.

Bransfield R, Mao C, Greenberg R Healthcare (Basel). 2024; 12(1).

PMID: 38200989 PMC: 10779437. DOI: 10.3390/healthcare12010083.

Neurodegeneration Markers in the Cerebrospinal Fluid of 100 Patients with Schizophrenia Spectrum Disorder.

Runge K, Balla A, Fiebich B, Maier S, von Zedtwitz K, Nickel K Schizophr Bull. 2022; 49(2):464-473.

PMID: 36200879 PMC: 10016411. DOI: 10.1093/schbul/sbac135.

References

King D, Cooper S, Earle J, Martin S, McFerran N, Wisdom G . Serum and CSF antibody titres to seven common viruses in schizophrenic patients. Br J Psychiatry. 1985; 147:145-9. DOI: 10.1192/bjp.147.2.145. View

Benros M, Mortensen P . Role of Infection, Autoimmunity, Atopic Disorders, and the Immune System in Schizophrenia: Evidence from Epidemiological and Genetic Studies. Curr Top Behav Neurosci. 2019; 44:141-159. DOI: 10.1007/7854_2019_93. View

Khandaker G, Stochl J, Zammit S, Lewis G, Jones P . Childhood Epstein-Barr Virus infection and subsequent risk of psychotic experiences in adolescence: a population-based prospective serological study. Schizophr Res. 2014; 158(1-3):19-24. PMC: 4561501. DOI: 10.1016/j.schres.2014.05.019. View

Tedla Y, Shibre T, Ali O, Tadele G, Woldeamanuel Y, Asrat D . Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiop Med J. 2011; 49(3):211-20. View

Stich O, Andres T, Gross C, Gerber S, Rauer S, Langosch J . An observational study of inflammation in the central nervous system in patients with bipolar disorder. Bipolar Disord. 2014; 17(3):291-302. DOI: 10.1111/bdi.12244. View

Endres D, Huzly D, Dersch R, Stich O, Berger B, Schuchardt F . Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study. Fluids Barriers CNS. 2017; 14(1):34. PMC: 5719745. DOI: 10.1186/s12987-017-0082-1. View

Endres D, Meixensberger S, Dersch R, Feige B, Stich O, Venhoff N . Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Transl Psychiatry. 2020; 10(1):279. PMC: 7419532. DOI: 10.1038/s41398-020-00967-3. View

Torrey E, Yolken R, Winfrey C . Cytomegalovirus antibody in cerebrospinal fluid of schizophrenic patients detected by enzyme immunoassay. Science. 1982; 216(4548):892-4. DOI: 10.1126/science.6281883. View

Flegr J, Prandota J, Sovickova M, Israili Z . Toxoplasmosis--a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS One. 2014; 9(3):e90203. PMC: 3963851. DOI: 10.1371/journal.pone.0090203. View

10.

Xiao J, Prandovszky E, Kannan G, Pletnikov M, Dickerson F, Severance E . Toxoplasma gondii: Biological Parameters of the Connection to Schizophrenia. Schizophr Bull. 2018; 44(5):983-992. PMC: 6101499. DOI: 10.1093/schbul/sby082. View

11.

Amminger G, McGorry P, Berger G, Wade D, Yung A, Phillips L . Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol Psychiatry. 2007; 61(10):1215-7. DOI: 10.1016/j.biopsych.2006.09.034. View

12.

Hottenrott T, Dersch R, Berger B, Rauer S, Eckenweiler M, Huzly D . The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS. 2015; 12:27. PMC: 4677451. DOI: 10.1186/s12987-015-0024-8. View

13.

Torrey E, Bartko J, Yolken R . Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr Bull. 2012; 38(3):642-7. PMC: 3329973. DOI: 10.1093/schbul/sbs043. View

14.

Dickerson F, Katsafanas E, Origoni A, Squire A, Khushalani S, Newman T . Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia. Schizophr Res. 2021; 228:193-197. PMC: 8023564. DOI: 10.1016/j.schres.2020.12.018. View

15.

Runge K, Tebartz van Elst L, Maier S, Nickel K, Denzel D, Matysik M . Cerebrospinal Fluid Findings of 36 Adult Patients with Autism Spectrum Disorder. Brain Sci. 2020; 10(6). PMC: 7349103. DOI: 10.3390/brainsci10060355. View

16.

de Witte L, van Mierlo H, Litjens M, Klein H, Bahn S, Osterhaus A . The association between antibodies to neurotropic pathogens and schizophrenia: a case-control study. NPJ Schizophr. 2016; 1:15041. PMC: 4849462. DOI: 10.1038/npjschz.2015.41. View

17.

Srikanth S, Ravi V, Poornima K, Shetty K, Gangadhar B, Janakiramaiah N . Viral antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic severity. Biol Psychiatry. 1994; 36(8):517-21. DOI: 10.1016/0006-3223(94)90615-7. View

18.

Breier A, Buchanan R, DSouza D, Nuechterlein K, Marder S, Dunn W . Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophr Res. 2018; 206:291-299. DOI: 10.1016/j.schres.2018.11.002. View

19.

Gotlieb-Stematsky T, ZONIS J, Arlazoroff A, Mozes T, Sigal M, Szekely A . Antibodies to Epstein-Barr virus, herpes simplex type 1, cytomegalovirus and measles virus in psychiatric patients. Arch Virol. 1981; 67(4):333-9. DOI: 10.1007/BF01314836. View

20.

Leweke F, Gerth C, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B . Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004; 254(1):4-8. DOI: 10.1007/s00406-004-0481-6. View